Review of clinical practice guidelines for hypoparathyroidism

Hypoparathyroidism is a rare disorder characterized by the absent or inappropriately decreased serum parathyroid hormone in the parathyroid glands, which is accompanied by impaired calcium-phosphorus metabolism.
The main etiology of hypoparathyroidism remains damage or removal of the parathyroid glands during neck surgery. In view of the incidence of thyroid cancer, primary hyperparathyroidism and other pathologies of the neck organs, which radical treatment can lead to the parathyroid gland impairment, an increased number of patients with hypoparathyroidism is expected. Autoimmune hypoparathyroidism is the second most common form of the disease, usually occurring as part of type 1 autoimmune polyglandular syndrome. Autoimmune hypoparathyroidism usually occurs in childhood and is characterized by a severe course of the disease, especially in the case of concomitant malabsorption syndrome.
Chronic hypoparathyroidism of any etiology requires lifelong multicomponent therapy, as well as careful monitoring and an individual approach to choose the optimal treatment strategy. In the absence of adequate follow-up, the risks of long-term complications significantly increase, particularly in the renal, cardiovascular systems; in the soft tissues and in the brain, it could lead to visual disturbances; pathology of the musculoskeletal system with a decreased bone remodeling and a potential risk of fractures, as well as to the neurocognitive disorders and an impaired health-related quality of life.
Timely diagnosis, rational medical therapy and management strategy may reduce the risks of short-term and long-term complications, frequency of hospitalizations and disability of patients, as well as improve the prognosis.
This review covers the main issues of Russian guidelines for the management of chronic hypoparathyroidism, approved in 2021, including laboratory and instrumental evaluation, treatment approaches and follow-up. This guidelines also include the recommendations for special groups of patients: with acute hypocalcemia, hypoparathyroidism during pregnancy.

1. Grodski S, Serpell J. Evidence for the Role of Perioperative PTH Measurement after Total Thyroidectomy as a Predictor of Hypocalcemia. World J Surg. 2008;32(7):1367-1373. doi: https://doi.org/10.1007/s00268-008-9545-5

2. Lorente-Poch L, Sancho JJ, Ruiz S, Sitges-Serra A. Importance of in situ preservation of parathyroid glands during total thyroidectomy. Br J Surg. 2015;102(4):359-367. doi: https://doi.org/10.1002/bjs.9676

3. Powers J, Joy K, Ruscio A, Lagast H. Prevalence and Incidence of Hypoparathyroidism in the United States Using a Large Claims Database. J Bone Miner Res. 2013;28(12):2570-2576. doi: https://doi.org/10.1002/jbmr.2004

4. Cutolo M. Autoimmune polyendocrine syndromes. Autoimmun Rev. 2014;13(2):85-89. doi: https://doi.org/10.1016/j.autrev.2013.07.006

5. Butters RR, Chattopadhyay N, Nielsen P, et al. Cloning and Characterization of a Calcium-Sensing Receptor from the Hypercalcemic New Zealand White Rabbit Reveals Unaltered Responsiveness to Extracellular Calcium. J Bone Miner Res. 1997;12(4):568-579. doi: https://doi.org/10.1359/jbmr.1997.12.4.568

6. Grigorieva IV, Thakker RV. Transcription factors in parathyroid development: lessons from hypoparathyroid disorders. Ann N Y Acad Sci. 2011;1237(1):24-38. doi: https://doi.org/10.1111/j.1749-6632.2011.06221.x

7. Veronese FM, et al. A comparison of three fluorophores (ThT, ANS, bis-ANS) for the detection of amyloid fibers and prefibrillar oligomeric assemblies. Clin. Orthop. Relat. Res. 2015;22(4):244-258.

8. Goldmuntz E. DiGeorge Syndrome: New Insights. Clin Perinatol. 2005;32(4):963-978. doi: https://doi.org/10.1016/j.clp.2005.09.006

9. Hannah M. Genetic developments in hypoparathyroidism For personal use only. Reproduce with permission from The Lancet Publishing Group. 2001. Vol. 357. P. 974–976.

10. Sanjad SA, Sakati NA, Abu-Osba YK, et al. A new syndrome of congenital hypoparathyroidism, severe growth failure, and dysmorphic features. Arch Dis Child. 1991;66(2):193-196. doi: https://doi.org/10.1136/adc.66.2.193

11. Blaine J, Chonchol M, Levi M. Renal Control of Calcium, Phosphate, and Magnesium Homeostasis. Clin J Am Soc Nephrol. 2015;10(7):1257-1272. doi: https://doi.org/10.2215/CJN.09750913

12. Saeed A, Khan M, Irwin S, Fraser A. Sarcoidosis presenting with severe hypocalcaemia. Ir J Med Sci. 2011;180(2):575-577. doi: https://doi.org/10.1007/s11845-009-0277-9

13. Anderson TJ, Ewen SWB. Amyloid in normal and pathological parathyroid glands. J Clin Pathol. 1974;27(8):656-663. doi: https://doi.org/10.1136/jcp.27.8.656

14. Yasmeen T. Riedel’s Thyroiditis: Report of a Case Complicated by Spontaneous Hypoparathyroidism, Recurrent Laryngeal Nerve Injury, and Horner’s Syndrome. J Clin Endocrinol Metab. 2002;87(8):3543-3547. doi: https://doi.org/10.1210/jc.87.8.3543

15. Horwitz CA, Myers WPL, Foote FW. Secondary malignant tumors of the parathyroid glands. Am J Med. 1972;52(6):797-808. doi: https://doi.org/10.1016/0002-9343(72)90086-1

16. Shoback D. Hypoparathyroidism. N Engl J Med. 2008;359(4):391-403. doi: https://doi.org/10.1056/NEJMcp0803050

17. Glazebrook GA. Effect of decicurie doses of radioactive iodine 131 on parathyroid function. Am J Surg. 1987;154(4):368-373. doi: https://doi.org/10.1016/0002-9610(89)90006-8

18. Winslow CP, Meyers AD. Hypocalcemia as a complication of radioiodine therapy. Am J Otolaryngol. 1998;19(6):401-403. doi: https://doi.org/10.1016/S0196-0709(98)90045-X

19. Guven A, Salman S, Boztepe H, et al. Parathyroid changes after high dose radioactive iodine in patients with thyroid cancer. Ann Nucl Med. 2009;23(5):437-441. doi: https://doi.org/10.1007/s12149-009-0270-4

20. Carpenter TO, Carnes DL, Anast CS. Hypoparathyroidism in Wilson’s Disease. N Engl J Med. 1983;309(15):873-877. doi: https://doi.org/10.1056/NEJM198310133091501

21. Joshi P, Lele V, Kapoor J. Dual ectopic thyroid - noninvasive diagnosis on radionuclide thyroid scan with SPECT/CT correlation: A case report and brief review of literature. Indian J Endocrinol Metab. 2013;17(2):359. doi: https://doi.org/10.4103/2230-8210.109687

22. Belhoul KM, Bakir ML, Saned M-S, et al. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major. Ann Hematol. 2012;91(7):1107-1114. doi: https://doi.org/10.1007/s00277-012-1412-7

23. Chern JPS, Lin K-H. Hypoparathyroidism in Transfusion-Dependent Patients With β-Thalassemia. J Pediatr Hematol Oncol. 2002;24(4):291-293. doi: https://doi.org/10.1097/00043426-200205000-00014

24. Aleem A, Al-Momen A-K, Al-Harakati MS, Hassan A, Al-Fawaz I. Hypocalcemia Due to Hypoparathyroidism in β-Thalassemia Major Patients. Ann Saudi Med. 2000;20(5-6):364-366. doi: https://doi.org/10.5144/0256-4947.2000.364

25. Clarke BL, Brown EM, Collins MT, et al. Epidemiology and Diagnosis of Hypoparathyroidism. J Clin Endocrinol Metab. 2016;101(6):2284-2299. doi: https://doi.org/10.1210/jc.2015-3908

26. Astor MC, Løvås K, Debowska A, et al. Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway. J Clin Endocrinol Metab. 2016;101(8):3045-3053. doi: https://doi.org/10.1210/jc.2016-1477

27. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. The Epidemiology of Nonsurgical Hypoparathyroidism in Denmark: A Nationwide Case Finding Study. J Bone Miner Res. 2015;30(9):1738-1744. doi: https://doi.org/10.1002/jbmr.2501

28. Rosato L, Avenia N, Bernante P, et al. Complications of Thyroid Surgery: Analysis of a Multicentric Study on 14,934 Patients Operated on in Italy over 5 Years. World J Surg. 2004;28(3):271-276. doi: https://doi.org/10.1007/s00268-003-6903-1

29. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Postsurgical Hypoparathyroidism-Risk of Fractures, Psychiatric Diseases, Cancer, Cataract, and Infections. J Bone Miner Res. 2014;29(11):2504-2510. doi: https://doi.org/10.1002/jbmr.2273

30. Davies L, Welch HG. Current Thyroid Cancer Trends in the United States. JAMA Otolaryngol Neck Surg. 2014;140(4):317. doi: https://doi.org/10.1001/jamaoto.2014.1

31. Cianferotti L. Classification of Hypoparathyroid Disorders. In: Frontiers of Hormone Research. ; 2019;15:127-138. doi: https://doi.org/10.1159/000491043

32. Chou CT, Siegel B, Mehta D. Stridor and apnea as the initial presentation of primary hypoparathyroidism. Int J Pediatr Otorhinolaryngol. 2016;80:30-32. doi: https://doi.org/10.1016/j.ijporl.2015.11.023

33. Bilezikian JP, Khan A, Potts JT, et al. Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26(10):2317-2337. doi: https://doi.org/10.1002/jbmr.483

34. Hadker N, Egan J, Sanders J, Lagast H, Clarke BL. Understanding the Burden of Illness Associated with Hypoparathyroidism Reported Among Patients in the Paradox Study. Endocr Pract. 2014;20(7):671-679. doi: https://doi.org/10.4158/EP13328.OR

35. Maeda SS, Moreira CA, Borba VZC, et al. Diagnosis and treatment of hypoparathyroidism: a position statement from the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2018;62(1):106-124. doi: https://doi.org/10.20945/2359-3997000000015

36. Khan AA, Koch CA, Van Uum S, et al. Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. Eur J Endocrinol. 2019;180(3):P1-P22. doi: https://doi.org/10.1530/EJE-18-0609

37. Brandi ML, Bilezikian JP, Shoback D, et al. Management of Hypoparathyroidism: Summary Statement and Guidelines. J Clin Endocrinol Metab. 2016;101(6):2273-2283. doi: https://doi.org/10.1210/jc.2015-3907

38. Maeda SS, Fortes EM, Oliveira UM, et al. Hypoparathyroidism and pseudohypoparathyroidism. Arq Bras Endocrinol Metabol. 2006;50(4):664-673. doi: https://doi.org/10.1590/S0004-27302006000400012

39. Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of Hypoparathyroidism: Etiologies and Clinical Features. J Clin Endocrinol Metab. 2016;101(6):2300-2312. doi: https://doi.org/10.1210/jc.2015-3909

40. Vokes T. et al. Hypoparathyroidism. Prim. Metab. Bone Dis. Disord. Miner. Metab. 2018;51:654-660.

41. Meola A, Vignali E, Matrone A, et al. Efficacy and safety of longterm management of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest. 2018;41(10):1221-1226. doi: https://doi.org/10.1007/s40618-018-0857-5

42. Asari R. Hypoparathyroidism After Total Thyroidectomy. Arch Surg. 2008;143(2):132-137. doi: https://doi.org/10.1001/archsurg.2007.55

43. Edafe O, Antakia R, Laskar N, et al. Systematic review and metaanalysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg. 2014;101(4):307-320. doi: https://doi.org/10.1002/bjs.9384

44. Selberherr A, Scheuba C, Riss P, Niederle B. Postoperative hypoparathyroidism after thyroidectomy: Efficient and costeffective diagnosis and treatment. Surgery. 2015;157(2):349-353. doi: https://doi.org/10.1016/j.surg.2014.09.007

45. Abbas A. Diagnosis and Management of Hypocalcaemia in Adults. In: Endocrinology and Diabetes. London: Springer London; 2015:133-140. doi: https://doi.org/10.1007/978-1-4471-2789-5_16

46. Hannan FM, Thakker RV. Investigating hypocalcaemia. BMJ. 2013;346(1):f2213-f2213. doi: https://doi.org/10.1136/bmj.f2213

47. Bollerslev J, Rejnmark L, Marcocci C, et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015;173(2):G1-G20. doi: https://doi.org/10.1530/EJE-15-0628

48. Ammirati AL. Chronic Kidney Disease. Rev Assoc Med Bras. 2020;66(1):s03-s09. doi: https://doi.org/10.1590/1806-9282.66.s1.3

49. Pocock SJ, Ashby D, Shaper AG, et al. Diurnal variations in serum biochemical and haematological measurements. J Clin Pathol. 1989;42(2):172-179. doi: https://doi.org/10.1136/jcp.42.2.172

50. Agus ZS. DISEASE OF THE MONTH, Hypomagnesemia. J Am Soc Nephrol. 1999;151:1616-1622.

51. Pearce SHS, Cheetham TD. Diagnosis and management of vitamin D deficiency. BMJ. 2010;340:142-147. doi: https://doi.org/10.1136/bmj.b5664

52. Kihara M, Yokomise H, Miyauchi A, Matsusaka K. Recovery of Parathyroid Function After Total Thyroidectomy. Surg Today. 2000;30(4):0333-0338. doi: https://doi.org/10.1007/s005950050596

53. Boyce AM, Shawker TH, Hill SC, et al. Ultrasound is Superior to Computed Tomography for Assessment of Medullary Nephrocalcinosis in Hypoparathyroidism. J Clin Endocrinol Metab. 2013;98(3):989-994. doi: https://doi.org/10.1210/jc.2012-2747

54. Colombo G, Solbiati M. Ultrasonography versus computed tomography for suspected nephrolithiasis. Intern Emerg Med. 2015;10(4):515-516. doi: https://doi.org/10.1007/s11739-015-1192-x

55. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: A Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013;28(11):2277-2285. doi: https://doi.org/10.1002/jbmr.1979

56. Sorensen MD, Thiel J, Dai JC, et al. In-Office Ultrasound Facilitates Timely Clinical Care at a Multidisciplinary Kidney Stone Center. Urol Pract. 2020;7(3):167-173. doi: https://doi.org/10.1097/UPJ.0000000000000082

57. Sternberg KM, Littenberg B. Trends in Imaging Use for the Evaluation and Followup of Kidney Stone Disease: A Single Center Experience. J Urol. 2017;198(2):383-388. doi: https://doi.org/10.1016/j.juro.2017.01.072

58. Valencia V, Moghadassi M, Kriesel DR, et al. Study of Tomography Of Nephrolithiasis Evaluation (STONE): Methodology, approach and rationale. Contemp Clin Trials. 2014;38(1):92-101. doi: https://doi.org/10.1016/j.cct.2014.03.006

59. Brisbane W, Bailey MR, Sorensen MD. An overview of kidney stone imaging techniques. Nat Rev Urol. 2016;13(11):654-662. doi: https://doi.org/10.1038/nrurol.2016.154

60. Kambadakone A, Andrabi Y, Patino M, et al. Advances in CT imaging for urolithiasis. Indian J Urol. 2015;31(3):185. doi: https://doi.org/10.4103/0970-1591.156924

61. Carter MR, Green BR. Renal calculi: emergency department diagnosis and treatment. Emerg. Med. Pract. United States. 2011;13(7):1-17.

62. Ather MH, Memon W, Aziz W, Sulaiman MN. Non-contrast CT in the Evaluation of Urinary Tract Stone Obstruction and Haematuria. In: Computed Tomography - Advanced Applications. InTech; 2017. doi: https://doi.org/10.5772/intechopen.68769

63. Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002;146(2):215-222. doi: https://doi.org/10.1530/eje.0.1460215

64. Saha S, Gantyala SP, Aggarwal S, et al. Long-term outcome of cataract surgery in patients with idiopathic hypoparathyroidism and its relationship with their calcemic status. J Bone Miner Metab. 2017;35(4):405-411. doi: https://doi.org/10.1007/s00774-016-0767-6

65. Goswami R, Sharma R, Sreenivas V, et al. Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism. Clin Endocrinol (Oxf). 2012;77(2):200-206. doi: https://doi.org/10.1111/j.1365-2265.2012.04353.x

66. Aggarwal S, Kailash S, Sagar R, et al. Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium. Eur J Endocrinol. 2013;168(6):895-903. doi: https://doi.org/10.1530/EJE-12-0946

67. Petrarca M, Scipioni R, Di Giosia P, et al. A case of brain calcifications in postsurgical hypoparathyroidism. Intern Emerg Med. 2017;12(1):113-115. doi: https://doi.org/10.1007/s11739-016-1430-x

68. Seedat F, Daya R, Bhana SA. Hypoparathyroidism Causing Seizures: When Epilepsy Does Not Fit. Case Rep Med. 2018;2018:1-4. doi: https://doi.org/10.1155/2018/5948254

69. Takamura Y, Miyauchi A, Yabuta T, et al. Attenuation of Postmenopausal Bone Loss in Patients with Transient Hypoparathyroidism After Total Thyroidectomy. World J Surg. 2013;37(12):2860-2865. doi: https://doi.org/10.1007/s00268-013-2207-2

70. Silva BC, Rubin MR, Cusano NE, Bilezikian JP. Bone imaging in hypoparathyroidism. Osteoporos Int. 2017. doi: https://doi.org/10.1007/s00198-016-3750-0

71. Rubin MR, Dempster DW, Zhou H, et al. Dynamic and Structural Properties of the Skeleton in Hypoparathyroidism. J Bone Miner Res. 2008;23(12):2018-2024. doi: https://doi.org/10.1359/jbmr.080803

72. Chen Q, Kaji H, Iu M-F, et al. Effects of an Excess and a Deficiency of Endogenous Parathyroid Hormone on Volumetric Bone Mineral Density and Bone Geometry Determined by Peripheral Quantitative Computed Tomography in Female Subjects. J Clin Endocrinol Metab. 2003;88(10):4655-4658. doi: https://doi.org/10.1210/jc.2003-030470

73. Orlova EM, Bukina AM, Kuznetsova ES, et al. Autoimmune Polyglandular Syndrome Type 1 in Russian Patients: Clinical Variants and Autoimmune Regulator Mutations. Horm Res Paediatr. 2010;73(6):449-457. doi: https://doi.org/10.1159/000313585

74. Bruserud Ø. et al. Polyendocrine syndrome type 1. 2016. № June. P. 1–10.

75. Meager A, Wadhwa M, Dilger P, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferonomega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 2003;132(1):128-136. doi: https://doi.org/10.1046/j.1365-2249.2003.02113.x

76. Meloni A, Furcas M, Cetani F, et al. Autoantibodies against Type I Interferons as an Additional Diagnostic Criterion for Autoimmune Polyendocrine Syndrome Type I. J Clin Endocrinol Metab. 2008;93(11):4389-4397. doi: https://doi.org/10.1210/jc.2008-0935

77. Sozaeva LS. The new immunological methods for diagnostics of type 1 autoimmune polyendocrine syndrome. Problems of Endocrinology. 2015;61(3):43-46. (In Russ.) doi: https://doi.org/10.14341/probl201561343-46

78. Zhang J, Liu H, Liu Z, et al. A Functional Alternative Splicing Mutation in AIRE Gene Causes Autoimmune Polyendocrine Syndrome Type 1. Gaunt TR, ed. PLoS One. 2013;8(1):e53981. doi: https://doi.org/10.1371/journal.pone.0053981

79. Rathod A, Bonny O, Guessous I, et al. Association of Urinary Calcium Excretion with Serum Calcium and Vitamin D Levels. Clin J Am Soc Nephrol. 2015;10(3):452-462. doi: https://doi.org/10.2215/CJN.12511213

80. Mitchell DM, Regan S, Cooley MR, et al. Long-Term Follow-Up of Patients with Hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(12):4507-4514. doi: https://doi.org/10.1210/jc.2012-1808

81. Rodriguez-Ortiz ME, Canalejo A, Herencia C, et al. Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. Nephrol Dial Transplant. 2014;29(2):282-289. doi: https://doi.org/10.1093/ndt/gft400

82. Mutnuri S, Fernandez I, Kochar T. Suppression of Parathyroid Hormone in a Patient with Severe Magnesium Depletion. Case Reports Nephrol. 2016;2016:1-3. doi: https://doi.org/10.1155/2016/2608538

83. Streeten EA, Mohtasebi Y, Konig M, et al. Hypoparathyroidism: Less Severe Hypocalcemia With Treatment With Vitamin D2 Compared With Calcitriol. J Clin Endocrinol Metab. 2017;102(5):1505-1510. doi: https://doi.org/10.1210/jc.2016-3712

84. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008;87(4):1080S-1086S. doi: https://doi.org/10.1093/ajcn/87.4.1080S

85. Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017;18(2):153-165. doi: https://doi.org/10.1007/s11154-017-9424-1

86. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84(1):18-28. doi: https://doi.org/10.1093/ajcn/84.1.18

87. Bilezikian JP, Brandi ML, Cusano NE, et al. Management of Hypoparathyroidism: Present and Future. J Clin Endocrinol Metab. 2016;101(6):2313-2324. doi: https://doi.org/10.1210/jc.2015-3910

88. Li D, Gao Y, Liu H, Huang X, et al. Use of thiazide diuretics for the prevention of recurrent kidney calculi: a systematic review and meta-analysis. J Transl Med. 2020;18(1):106. doi: https://doi.org/10.1186/s12967-020-02270-7

89. Santos F. Hypercalciuria Associated With Long-term Administration of Calcitriol (1,25-Dihydroxyvitamin D3). Am J Dis Child. 1986;140(2):139. doi: https://doi.org/10.1001/archpedi.1986.02140160057032

90. Bilezikian JP, Brandi ML, Cusano NE, et al. Management of Hypoparathyroidism: Present and Future. J Clin Endocrinol Metab. 2016;101(6):2313-2324. doi: https://doi.org/10.1210/jc.2015-3910

91. Porter RH, Cox BG, Heaney D, et al. Treatment of Hypoparathyroid Patients with Chlorthalidone. N Engl J Med. 1978;298(11):577-581. doi: https://doi.org/10.1056/NEJM197803162981101

92. Khan MI, Waguespack SG, Hu MI. Medical Management Of Postsurgical Hypoparathyroidism. Endocr Pract. 2011;17:18-25. doi: https://doi.org/10.4158/EP10302.RA

93. Davies M, Taylor CM, Hill LF, Stanbury SW. 1,25-dihydroxycholecalciferol in hypoparathyroidism. Lancet. 1977;309(8002):55-59. doi: https://doi.org/10.1016/S0140-6736(77)91077-7

94. Hill LF, Davies M, Taylor CM, Stanbury SW. Treatment of hypoparathyroidism with 1,25-dihydroxycholecalciferol. Clin Endocrinol (Oxf ). 1976;5(s1):s167-s173. doi: https://doi.org/10.1111/j.1365-2265.1976.tb03824.x

95. Kanis JA, Russell RGG, Smith R. Physiological and therapeutic differences between vitamin d, its metabolites and analogues. Clin Endocrinol (Oxf ). 1977;7(S1):191-201. doi: https://doi.org/10.1111/j.1365-2265.1977.tb03381.x

96. Okano K, Furukawa Y, Morii H, Fujita T. Comparative Efficacy of Various Vitamin D Metabolites in the Treatment of Various Types of Hypoparathyroidism. J Clin Endocrinol Metab. 1982;55(2):238-243. doi: https://doi.org/10.1210/jcem-55-2-238

97. Straub DA. Calcium Supplementation in Clinical Practice: A Review of Forms, Doses, and Indications. Nutr Clin Pract. 2007;22(3):286-296. doi: https://doi.org/10.1177/0115426507022003286

98. Klein R, et al. The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF CHICAGO LIBRARIES on August 20, 2013. For personal use only. No other uses without permission. From the NEJM Archive. Copyright © 2010 Massachusetts Medical Society. All rights. 1981.

99. Kurzel R, Hagen G. Use of Thiazide Diuretics to Reduce the Hypercalciuria of Hypoparathyroidism During Pregnancy. Am J Perinatol. 1990;7(04):333-336. doi: https://doi.org/10.1055/s-2007-999516

100. Newman GH, Wade M, Hosking DJ. Effect of bendrofluazide on calcium reabsorption in hypoparathyroidism. Eur J Clin Pharmacol. 1984;27(1):41-46. doi: https://doi.org/10.1007/BF02395204

101. Parfitt AM. Thiazide-Induced Hypercalcemia in Vitamin D-Treated Hypoparathyroidism. Ann Intern Med. 1972;77(4):557. doi: https://doi.org/10.7326/0003-4819-77-4-557

102. Murdoch D, Forrest G, Davies D, McInnes G. A comparison of the potassium and magnesium-sparing properties of amiloride and spironolactone in diuretic-treated normal subjects. Br J Clin Pharmacol. 1993;35(4):373-378. doi: https://doi.org/10.1111/j.1365-2125.1993.tb04153.x

103. Santos F. Hypercalciuria Associated With Long-term Administration of Calcitriol (1,25-Dihydroxyvitamin D3). Am J Dis Child. 1986;140(2):139. doi: https://doi.org/10.1001/archpedi.1986.02140160057032

104. Underbjerg L, Sikjaer T, Rejnmark L. Long-Term Complications in Patients With Hypoparathyroidism Evaluated by Biochemical Findings: A Case-Control Study. J Bone Miner Res. 2018;33(5):822-831. doi: https://doi.org/10.1002/jbmr.3368

105. Cannata-Andia JB, Rodriguez-Garcia M. Hyperphosphataemia as a cardiovascular risk factor - how to manage the problem. Nephrol Dial Transplant. 2002;17(S11):16-19. doi: https://doi.org/10.1093/ndt/17.suppl_11.16

106. Bandeira LC, Rubin MR, Cusano NE, Bilezikian JP. Vitamin D and Hypoparathyroidism. In: Frontiers of Hormone Research. 2018;50:114-124. doi: https://doi.org/10.1159/000486075

107. Pigarova EA, Rozhinskaya LYa, Belaya ZhE, et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60-84. (In Russ.) doi: https://doi.org/10.14341/probl201662460-84

108. Erbil Y, Ozbey NC, Sari S, et al. Determinants of postoperative hypocalcemia in vitamin D-deficient Graves’ patients after total thyroidectomy. Am J Surg. 2011;201(5):685-691. doi: https://doi.org/10.1016/j.amjsurg.2010.04.030

109. Erbil Y, Barbaros U, Temel B, et al. The impact of age, vitamin D3 level, and incidental parathyroidectomy on postoperative hypocalcemia after total or near total thyroidectomy. Am J Surg. 2009;197(4):439-446. doi: https://doi.org/10.1016/j.amjsurg.2008.01.032

110. Erbil Y. Predictive Value of Age and Serum Parathormone and Vitamin D3 Levels for Postoperative Hypocalcemia After Total Thyroidectomy for Nontoxic Multinodular Goiter. Arch Surg. 2007;142(12):1182-1187. doi: https://doi.org/10.1001/archsurg.142.12.1182

111. Alkhalili E, Ehrhart MD, Ayoubieh H, Burge MR. Does Pre-Operative Vitamin D Deficiency Predict Postoperative Hypocalcemia After Thyroidectomy? Endocr Pract. 2017;23(1):5-9. doi: https://doi.org/10.4158/EP161411.OR

112. Unsal IO, Calapkulu M, Sencar ME, et al. Preoperative Vitamin D Levels as a Predictor of Transient Hypocalcemia and Hypoparathyroidism After Parathyroidectomy. Sci Rep. 2020;10(1):9895. doi: https://doi.org/10.1038/s41598-020-66889-8

113. Carvalho GB de, Giraldo LR, Lira RB, et al. Preoperative vitamin D deficiency is a risk factor for postoperative hypocalcemia in patients undergoing total thyroidectomy: retrospective cohort study. Sao Paulo Med J. 2019;137(3):241-247. doi: https://doi.org/10.1590/1516-3180.2018.0336140319

114. Malik MZ, Mirza AA, Farooqi SA, et al. Role of Preoperative Administration of Vitamin D and Calcium in Postoperative Transient Hypocalcemia after Total Thyroidectomy. Cureus. 2019;11(4):e4579. doi: https://doi.org/10.7759/cureus.4579

115. Kirkby-Bott J, Markogiannakis H, Skandarajah A, et al. Preoperative vitamin D deficiency predicts postoperative hypocalcemia after total thyroidectomy. World J Surg. 2011;35(2):324-330. doi: https://doi.org/10.1007/s00268-010-0872-y

116. Chang YK, Lang BHH. To identify or not to identify parathyroid glands during total thyroidectomy. Gland Surg. 2017;6(S1):S20-S29. doi: https://doi.org/10.21037/gs.2017.06.13

117. Hallgrimsson P, Nordenström E, Almquist M, Bergenfelz AOJ. Risk Factors for Medically Treated Hypocalcemia after Surgery for Graves’ Disease: A Swedish Multicenter Study of 1,157 Patients. World J Surg. 2012;36(8):1933-1942. doi: https://doi.org/10.1007/s00268-012-1574-4

118. Bergenfelz A, Jansson S, Kristoffersson A, et al. Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients. Langenbeck’s Arch Surg. 2008;393(5):667-673. doi: https://doi.org/10.1007/s00423-008-0366-7

119. Alhefdhi A, Mazeh H, Chen H. Role of Postoperative Vitamin D and/or Calcium Routine Supplementation in Preventing Hypocalcemia After Thyroidectomy: A Systematic Review and MetaCAnalysis. Oncologist. 2013;18(5):533-542. doi: https://doi.org/10.1634/theoncologist.2012-0283

120. Grzegory A, Pomorski L. Perioperative calcium and vitamin D supplementation in patients undergoing thyroidectomy — literature review. Polish J Surg. 2018;90(4):34-38. doi: https://doi.org/10.5604/01.3001.0012.0975

121. Bai B, Chen Z, Chen W. Risk factors and outcomes of incidental parathyroidectomy in thyroidectomy: A systematic review and meta-analysis. PLoS One. 2018;13(11):11-17. doi: https://doi.org/10.1371/journal.pone.0207088

122. Cui Q, Li Z, Kong D, et al. A prospective cohort study of novel functional types of parathyroid glands in thyroidectomy. Medicine (Baltimore). 2016;95(52):e5810. doi: https://doi.org/10.1097/MD.0000000000005810

123. Oran E, Yetkin G, Mihmanli M, et al. The risk of hypocalcemia in patients with parathyroid autotransplantation during thyroidectomy. Turkish J Surg. 2016;32(1):6-10. doi: https://doi.org/10.5152/UCD.2015.3013